source
- Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechsFrazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion for its long-running public fund.Fierce Biotech · 6h ago↗ source
- Solstice Oncology secures $225M Series A to launch FDA-cleared Phase 2 CTLA-4 antibody trialSolstice Oncology, a cancer-focused startup that emerged from stealth in February, announced a $225 million Series A financing round to fund its early-stage programs. The capital will be used to a…